Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4474 in Knee Osteoarthritis Pain
NCT02997696Phase 2Terminated
- Sponsor
- Ono Pharmaceutical
- Start
- Jan 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of ONO-4474 in knee osteoarthritis (OA) (3 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Change from baseline in mean daily average index knee pain while walking at 4 weeks. Started Jan 2017; status: terminated.
02
Drugs
ONO-4474
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02997696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02997696.